Tafinlar is a Oral Capsule in the Human Prescription Drug category. It is labeled and distributed by Novartis Pharmaceuticals Corporation. The primary component is Dabrafenib Mesylate.
| Product ID | 0078-0682_058c0b15-6711-4cf3-9c07-6892bad16e38 |
| NDC | 0078-0682 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Tafinlar |
| Generic Name | Dabrafenib |
| Dosage Form | Capsule |
| Route of Administration | ORAL |
| Marketing Start Date | 2016-04-12 |
| Marketing Category | NDA / NDA |
| Application Number | NDA202806 |
| Labeler Name | Novartis Pharmaceuticals Corporation |
| Substance Name | DABRAFENIB MESYLATE |
| Active Ingredient Strength | 50 mg/1 |
| Pharm Classes | Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA],Organic Anion Transporter 1 Inhibitors [MoA],Organic Anion Transporter 3 Inhibitors [MoA],Breast Cancer Resistance Protein Inhibitors [MoA],Kinase Inhibitor [EPC],Protein Kinase Inhibitors [MoA],Cytochrome P450 3A4 Inducers [MoA],Cytochrome P450 2B6 Inducers [MoA],Cytochrome P450 2C8 Inducers [MoA],Cytochrome P450 2C9 Inducers [MoA],Cytochrome P450 2C19 Inducers [MoA],Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2021-12-31 |
| Marketing Start Date | 2016-04-12 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | NDA |
| Application Number | NDA202806 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | EA |
| Marketing Start Date | 2016-04-12 |
| Ingredient | Strength |
|---|---|
| DABRAFENIB MESYLATE | 50 mg/1 |
| SPL SET ID: | fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 0078-0681 | Tafinlar | dabrafenib |
| 0078-0682 | Tafinlar | dabrafenib |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() TAFINLAR 85094477 3976920 Live/Registered |
NOVARTIS PHARMA AG 2010-07-28 |